Product Description
Baricitinib (formerly INCB28050, LY3009104) is an oral JAK1 and JAK2 inhibitor. Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy. The related compound in JAK inhibitor is Tofacitinib, currently approved for the treatment of rheumatoid arthritis in the United States.
| Payment Terms: | TT/Western Union |
| |
Product Image
Img 1
Send Inquiry to this Member
Related Products of this Company
This member assumes full responsibility for the content of this listing. DIYTrade accepts no responsibility whatsoever in respect of such content.
To report fraudulent or illegal content, please
click here.
China Suppliers Quick Searching:
,
